ANI Pharmaceuticals' GAAP loss for 3 months of 2022 was $20.13 million, compared to a profit of $0.086 million in the previous year. Revenue increased 18.3% to $64.477 million from $54.521 million a year earlier.

ANI Pharmaceuticals' GAAP loss for 2021 was $42.603 million, up 88.9% from $22.548 million in the prior year. Revenue increased 3.7% to $216.136 million from $208.475 million a year earlier.

ANI Pharmaceuticals has completed the acquisition of Novitium Pharma, a generic pharmaceutical company with its own line of such drugs. ANI will pay $89.5 million and 2,466,654 of its common stock for about $74 million. Novitium is also entitled to receive an additional $25 million if certain financial targets related to generic sales are achieved.

ANI Pharmaceuticals' GAAP loss for 9M 2021 was $18.467 million, down 2.4% from $18.913 million in the previous year. Revenue increased 2.6% to $155.207 million from $151.223 million a year earlier.